Ad Code: Ilumya - Display Banners Conference - CPE - MAY - 109299

Baricitinib significantly improved scalp hair regrowth, with 80% or more scalp hair coverage in 42% of adolescents with severe alopecia areata (AA) at 36 weeks, with a favorable safety profile. Similarly, eyebrow and eyelash regrowth were also significantly improved.

Once-daily ICP-488, a selective oral tyrosine kinase 2 (TYK2) inhibitor, significantly improved PASI scores in patients with moderate-to-severe plaque psoriasis compared with placebo at week 12, with a safety profile similar to placebo.

New findings from the phase 3 ICONIC-LEAD trial suggest that once-daily oral icotrokinra demonstrated significant, durable skin clearance and a safety profile similar to placebo in patients with plaque psoriasis.

Upadacitinib efficacy and safety in treating palmoplantar pustulosis (PPP) revealed rapid and sustained pustule clearance with an acceptable safety profile. The researchers also introduced a novel mouse model to further advance PPP research by providing insights into disease mechanisms and potential treatment targets.

The phase 3 ROCKET-Horizon trial testing rocatinlimab, a first-in-class investigational T-cell rebalancing therapy, meets its co-primary end points in week 24: EASI75 response was 32.8% for rocatinlimab versus 13.7% for moderate-to-severe atopic dermatitis (AD).

A new study suggests inadequate counseling and limited resources are among several barriers to educating patients on psoriasis’s link to cardiometabolic issues.

Psoriasis affects 7.5M+ U.S. adults, with new targeted treatments, diet links, and patient-centered care improving outcomes. Advances offer hope for better management.

Review highlights emerging psoriasis therapies, including IL-21, Snora73, gut microbiome, and natural treatments, offering new patient-centered options.

The 2025 AAD Meeting features key psoriasis sessions on therapies, JAK inhibitors, obesity links, patient care gaps, and cutting-edge treatment advances.